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Abstract
Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of
which the metacestode (larval) stages cause the neglected diseases cystic
echinococcosis (CE) and alveolar echinococcosis (AE), respectively. The
benzimidazoles albendazole and mebendazole are presently used for the
chemotherapeutical treatment, alone or prior to and after surgery. However, in
AE these benzimidazoles do not appear to be parasiticidal in vivo. In addition,
failures in drug treatments as well as the occurrence of side-effects have been
reported, leading to discontinuation of treatment or to progressive disease.
Therefore, new drugs are needed to cure AE and CE. Strategies that are currently
employed in order to identify novel chemotherapeutical treatment options
include in vitro and in vivo testing of broad-spectrum anti-infective drugs or
drugs that interfere with unlimited proliferation of cancer cells. The fact that the
genome of E. multilocularis has recently been sequenced has opened other
avenues, such as the selection of novel drugs that interfere with the parasite
signalling machinery, and the application of in silico approaches by employing
the Echinococcus genome information to search for suitable targets for
compounds of known mode of action.
Impact of Echinococcus
Echinococcosis, caused by larval stages of Echinococcus
(Cestoda, Plathelminthes), is a life-threatening disease
affecting humans and livestock. Four distinct species
within the genus Echinococcus have been identified,
i.e. Echinococcus multilocularis, E. granulosus, E. vogeli and
E. oligarthrus (Thompson, 1986). At present, seven to nine
species are described (Nakao et al., 2007; Varcasia et al.,
2008). All species are potentially zoonotic, two being of
significant medical importance, namely E. multilocularis
(small fox tapeworm) as the most pathogenic, and
E. granulosus (dog tapeworm) as the most common
(Rausch, 1995; McManus et al., 2003). Echinococcus
multilocularis infection causes alveolar echinococcosis
(AE) in intermediate hosts and humans, and is restricted
to the northern hemisphere. The current incidence rate
for Germany, 0.07/100,000 persons, is probably under-
estimated by a factor of 3–5 (Jorgensen et al., 2008). In
contrast, E. granulosus, the causative agent of cystic
echinococcosis (CE), occurs worldwide (Schantz et al.,
1995) with hyperendemic areas in South America, North
and East Africa, southern Europe and Central Asia
(McManus et al., 2003). Both, AE and CE are neglected
diseases, and emergence (or re-emergence), especially in
developing countries, is likely (McManus et al., 2003;
Eckert & Deplazes, 2004), with an increasing economic
impact due to the necessity of life-long treatments
(Torgerson, 2003).
Biology of Echinococcus
The habitat of the adult worms is the intestine of their
respective final host (dogs for E. granulosus, foxes, dogs
and cats for E. multilocularis), where sexual reproduction
and subsequent egg production take place. Faecal
shedding spreads the eggs into the environment, where
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they are accidentally taken up by suitable intermediate
hosts, such as small rodents for E. multilocularis, and
cattle and sheep for E. granulosus. Humans represent
an aberrant intermediate host that acquires disease
through the accidental ingestion of eggs, with serious
consequences. Eggs contain the first larval stage, the
oncosphere, which actively penetrates the intestinal
lining, and migrates via blood and lymphatic vessels to
the target sites. Most affected organs in humans are the
liver for E. multilocularis, and the liver, lung and other
sites in the case of E. granulosus. There, these oncospheres
develop into metacestodes representing the second larval
stage and the disease-causing stage. Within these
metacestodes, protoscolex development takes place in
natural intermediate hosts. If an infected intermediate
host is ingested by a suitable definitive host, the life cycle
is concluded. Protoscolex development in humans has
only rarely been described (Eckert et al., 1983).
Metacestodes are fluid-filled vesicles that can be
separated into two distinct structural entities, namely a
cellular and an acellular compartment (see fig. 1).
The outer acellular surface of the metacestode is formed
by the laminated layer, a carbohydrate-rich structure
synthesized by the parasite, which, in terms of thickness,
is much more prominent in E. granulosus metacestodes
(Gottstein & Hemphill, 1997). In addition, E. granulosus
metacestodes are surrounded by a very prominent host-
derived fibrous capsule, the adventitial layer composed of
Fig. 1. Morphology and ultrastructure of Echinococcus metacestodes. (A) A lower magnification view of an opened metacestode
exposing the inner germinal layer (GL)-associated tissue, and the acellular laminated layer representing the parasite surface (LL).
Scale bar ¼ 2.5mm. (B) A higher magnification of the GL. Scale bar ¼ 380mm. (C) TEM through the metacestode wall. The parasite tissue
is composed of the tegument (Te), a syncytial layer adjacent to the LL, with numerous microtriches (arrows) protruding into the LL.
The germinal layer is composed of different cell types such as connective tissue cells, muscle cells (mus), glycogen storage cells (glyc),
and undifferentiated cells with a large nucleus and nucleolus (uc). Scale bar ¼ 2.5mm.
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host connective tissue. The laminated layer plays a crucial
role in the survival strategy of the parasite by modulating
immunological and physiological reactions on the part of
the host (Gottstein et al., 2002; reviewed in Siles-Lucas &
Hemphill, 2002; Walker et al., 2004a; Gottstein et al., 2006).
The actual larval tissue is formed by the germinal layer, its
distal part, the tegument, being directly associated with
the inner surface of the laminated layer. The tegument is
characterized by microvilli-like extensions termed micro-
triches, which protrude well into the matrix of the
laminated layer, thus increasing the resorbing surface of
the parasite. In addition, the germinal layer contains
highly differentiated cell types, including connective
tissue, muscle cells and glycogen storage cells, as well as
many undifferentiated cells (Eckert et al., 1983).
Typically, the fully mature E. granulosus metacestode
(i.e. hydatid cyst) is a single-chambered or septated, but
unilocular, cyst that shows expansive growth and causes
thereby compression of neighbouring tissue, resulting in
organ dysfunction and disease (Kern, 2003, 2006). In
E. multilocularis infection, the metacestode represents a
multi-vesicular structure that reproduces asexually, by
exogenous formation and budding of daughter vesicles,
which resembles progressive tumour-like growth
(Ohbayashi et al., 1971; Ali-Khan et al., 1983). This leads
to the formation of a large and heterogeneous parasitic
mass consisting of mostly peripheral actively proliferat-
ing sites and, in many cases, centrally located necrotic
tissue. Metastasis formation may occur in other organs
due to release of germinal layer cells into the blood or
lymph system (Ali-Khan et al., 1983; Eckert et al., 1983;
Mehlhorn et al., 1983). Spontaneous cure of AE leading to
calcified lesions is possible, but it is not known how
commonly this occurs (reviewed in Gottstein &Hemphill,
1997; Vuitton et al., 2006). In fact, mass screenings in
endemic areas have shown that the number of established
AE infections in humans is far lower than the number of
humans exposed to the eggs of the parasite and therefore
sero-positive (Rausch et al., 1987; Bresson-Hadni et al.,
1994; Bartholomot et al., 2002). Thus, innate or acquired
immunity is able to control the parasite after infection.
This opens the door for the development of appropriate
immunotherapeutical tools.
Current therapies
Traditionally, treatment of echinococcosis relies on
surgery and/or chemotherapy, depending on different
factors such as metacestode size and location, viability
status, the interaction between the expanding parasite
and the adjacent host tissue, bacterial and fungal
infection, and potential complications related to cyst
rupture and spillage of protoscoleces (Kern, 2003, 2006).
In CE, radical resection of the cyst mass represents the
traditional treatment strategy and is, in many instances,
accompanied by chemotherapy. Protoscolicidal sub-
stances are often applied since there is a risk of spilling
of cyst fluid containing protoscoleces, which would be
responsible for metastasis formation (Stey & Jost, 1993;
Pawlowski, 1997; Kern, 2003, 2006). PAIR (puncture,
aspiration, injection, re-aspiration) is a technique intro-
duced in the mid-eighties. It includes percutaneous
puncture of the cysts under ultrasonic guidance, aspira-
tion of substantial amounts of cyst fluid, injection
of protoscolicidal substance (e.g. 95% ethanol), and
re-aspiration of the fluid cyst content after 15–20min.
PAIR has been used in several hundred patients.
Nevertheless, the efficacy and potential risks have not
been fully evaluated, and more long-term studies are
needed (Morris & Richards, 1992; Brunetti et al., 2004;
Eckert & Deplazes, 2004).
For inoperable cases, chemotherapy with the
benzimidazoles albendazole (ABZ), a broad-spectrum
anthihelminthic, and mebendazole (MBZ) and the
heterocyclic pyrazinoisoquinoline derivative praziquan-
tel (PZQ) remains the only option. Pawlowski et al. (2001)
have evaluated over 2000 well-documented inoperable
cases of CE treated with benzimidazoles. When evalua-
ted up to 12 months after initiation of chemotherapy,
30% of patients showed cyst disappearance, 50–70%
exhibited cyst degeneration indicating improvement, and
in 20–30% of patients E. granulosus metacestodes did not
respond to chemotherapy (Pawlowski et al., 2001). PZQ
was proposed to be used alongside with benzimidazoles
in CE-patients. PZQ exhibited a high efficacy against
protoscoleces and metacestodes in animal experiments
(Urrea-Paris et al., 1999, 2001), and the combined
treatment with ABZ and PZQ given during the month
prior to surgery increased the number of human patients
with non-viable protoscoleces, as compared to therapy
with ABZ alone (Cobo et al., 1998).
For the treatment of AE, surgery is always
accompanied by chemotherapy using benzimidazoles,
which should last for at least 2 years post-surgery, and
monitoring of patients should be continued for 10 years
(Pawlowski et al., 2001). Inoperable AE cases must
undergo long-term chemotherapy, often life-long, which
is based on ABZ and/or MBZ (Reuter et al., 2000, 2004).
Extensive animal experimentation and observations in
human patients sufferering from AE have demonstrated
that ABZ and MBZ exhibit a parasitostatic rather than a
parasitocidal effect (El-On, 2002; Reuter et al., 2004).
Therefore, recurrence rates after interruption of therapy
are high. Nevertheless, clinical studies have shown that
chemotherapy has significantly increased the 10-year
survival rate of inoperable or non-radically operated AE
patients from 6–25% to 80–83% (Ammann & Eckert,
1995; Eckert & Deplazes, 2004).
Adverse reactions against benzimidazoles under
long-term chemotherapy include elevation of trans-
aminases, proteinuria, loss of hair, gastrointestinal
disturbances, neurological symptoms (vertigo/dizzi-
ness), leucopenia, headache, abnormal liver biopsy,
abdominal pain, fever, urticaria, thrombocytopenia,
allergic shock (due to cyst collapse and liberation of
E. granulosus cyst fluid) and bonemarrow toxicity. A study
comprised of 3282 echinococcosis patients treated with
ABZ showed that most side-effects were associated
with the gastrointestinal tract but no fatal cases involving
ABZ therapy were described. In 3.8% of these cases,
permanent discontinuation of treatment had to be
undertaken (reviewed by Pawlowski, 1997; Kern, 2003).
As suggested by animal experimentation, MBZ and ABZ
may induce embryotoxic or teratogenic effects, and it is
recommended that these drugs are not used for the
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treatment of pregnant women (Horton, 1989, 1997).
Constant monitoring of drug serum levels is suggested
in order to avoid toxic reactions.
Taken together, besides benzimidazoles, novel drugs
are required.
Methods for in vitro and in vivo evaluation of anti-
echinococcal drugs
Both in vitro and in vivo laboratory models have been
used for drug evaluation (reviewed in Siles-Lucas &
Hemphill, 2002). Historically, the primary assessment
of anti-echinococcal drug candidates has often been
performed in mice or gerbils by evaluating parasite mass
and/or health parameters of the host. This has led to
the extensive use of animal experimentation, andhas often
yielded inconclusive results. In vitro culture of Echinococ-
cusmetacestodes has subsequently proven to be a suitable
tool for the primary assessment of drug susceptibility by
counting damaged metacestodes under the light micro-
scope, followed by ultrastructural analysis by scanning
and transmission electron microscopy (see, for example,
Ingold et al., 1999). A rapid test for viability is eosin
exclusion (Lawton et al., 2001). Anothermethod consists in
sampling culture supernatant and measuring enzymes
released from damaged metacestodes (e.g. Stettler et al.,
2001). Furthermore, viability and proliferative capacity of
metacestodes can be analysed by quantification of 14-3-3
gene expression (Matsumoto et al., 2006; Spicher et al.,
2008a). In vitro cultures also represent an ideal model
system for studies on drug uptake and respective
metabolic changes imposed upon the parasite (Hemphill
et al., 2002a). In vitro chemotherapy studies on CE have
mostly, but not exclusively, focused on protoscoleces,
since these are easily cultured. Conversely, their differen-
tiation intometacestodes is a time-consuming process and
can easily take 4–6 months (Walker et al. 2004a, b). More
recently, optimized in vitro culture conditions have been
developed by Brehm and co-workers (Spiliotis et al., 2004;
reviewed by Brehm & Spiliotis, 2008). These in vitro
methods reduce the number of animal experiments, but
do not render them completely obsolete. In order to assess
long-term viability and infectivity, metacestodes treated
with the best drug candidates are still injected into rodents
(Hemphill et al., 2002).
In vitro and in vivo studies with benzimidazoles
Since benzimidazoles, especially ABZ, are the most
relevant chemotherapeutics for the treatment of AE and
CE to date, most preclinical in vitro and in vivo studies
have been performedwith these compounds, with a focus
on comparing the activities of different benzimidazole
derivatives, and on different formulations and modes of
application. In rodents, efficacies of oral administration
are dependent on the duration of treatment and the age of
the parasite. Efficacy rises with prolongation of the
treatment, but is distinctly lower for infections that have
been persisting for extended periods of time (Wangoo
et al., 1987). Increased doses produce better results,
although clear parasitocidal effects are never completely
achieved (Taylor et al., 1989). Moreover, phenomena
related to drug resistance have been described (Morris
& Taylor, 1990). Conflicting reports exist on the most
suitable mode of administration of benzimidazoles.
It was postulated that parenteral administration of
benzimidazoles resulted in a higher efficacy than
other routes in animals experimentally infected with
E. multilocularis (reviewed in Siles-Lucas & Hemphill,
2002). Combinations of ABZ with other compounds were
tested in order to obtain better treatment efficacies.
For instance, synergistic effects were reported for
combinations of ABZ with the dipeptide methyl ester
Phe-Phe-OMe (Sarciron et al., 1997). In addition, novel
formulations of benzimidazoles, either as pro-drugs
(Walchshofer et al., 1990), liposome-entrapped com-
pounds (Wen et al., 1996) or colloidal, intravenously
injectable formulations (Rodrigues et al., 1995) were tested
in rodents and showed enhanced efficacy at lower doses
than the parental compounds. However, these studies
have not really been translated into clinical applications,
with one exception. Chai et al. (2004) reported on
improved efficacy of ABZ emulsion compared to ABZ
tablets or capsules for the treatment of liver CE.
Experimental prophylactic therapy of E. granulosus pro-
toscoleces was carried out as a model that would mimic
spillage during surgery, by treating protoscoleces with
PZQ (Urrea-Paris et al., 2001) or a combination of PZQ
and ABZ (Casado et al., 2001) prior to injection into mice.
Against E. granulosus infection in rodents, a combination
of fenbendazol and netobimin (Garcia-Llanazares et al.,
1997) showed synergistic effects, allowing the adminis-
tration of lower drug dosage. Oxfendazole, like ABZ, is a
benzimidazole, used in veterinary medicine for the
control of nematode infections, and has a similar
antimicrobial spectrum but a longer half-life. Experimen-
tal treatments of naturally E. granulosus-infected sheep
and goats suggested that oxfendazole may be as
efficacious as ABZ, but does not require daily uptake of
the drug (Blanton et al., 1998; Dueger et al., 1999). Another
benzimidazole derivative effective againt E. multilocularis
metacestodes in vitro is methiazole (Reuter et al., 2006).
Mode of action of benzimidazoles
When in vitro cultures of metacestodes were treated
with ABZ, microtubular ultrastructure was affected
(Rubino et al., 1983; Ingold et al., 1999) suggesting that
ABZ interfered with tubulin polymerization (Lacey,
1990). Molecular genetics revealed that sensitivity to
benzimidazoles in evolutionary distant organisms such as
fungi, nematodes, platyhelmithes and various protozoa
was correlated with the presence of specific alleles of
b-tubulin genes (Driscoll et al., 1989; Katiyar et al., 1994;
Kwa et al., 1995; Henriquez et al., 2008), the substitution of
Phe to Tyr in position 200 being sufficient for switching
from benomyl sensitivity to resistance in nematodes (Kwa
et al., 1995). Molecular modelling of the putative ABZ
binding site in ABZ-resistant Acanthamoeba b–tubulin
revealed 13 residues, four of which showed sequence
variation as compared to tubulins of sensitive organisms.
Resistance was conferred when, besides Phe200,
Phe167 was also replaced (Henriquez et al., 2008).
In E. multilocularis, cDNAs of three b-tubulin genes
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were identified, two of them having a Phe in position 200
(Brehm et al., 2000). The IC50 values of ABZ in organisms
regarded as sensitive to ABZ was between 30nM in the
protozoon Giardia lamblia (Katiyar et al., 1994, confirmed
by own observations) and more than 10mM in nematode
larvae (Satou et al., 2002). Clear-cut IC50 values for E.
multilocularismetacestodes are not found in the literature.
Metacestodes treated with nearly 40mM albendazole-
sulphoxide (ABZSO) showed symptoms with increasing
severity over time (e.g. Ingold et al., 1999) and totally
disintegrated only after 21 days (Reuter et al., 2006). This
indicates that cytotoxic effects of ABZ (or its metabolites)
due to tubulin depolymerization may be hampered in
Echinococcus by: (1) the presence of an ABZ-insensitive
b-tubulin complementing the sensitive isoform; (2) rapid
ABZ catabolism; (3) toxicity of ABZ catabolites rather
than ABZSO itself; and/or (4) a good regenerative power
due to insensitive stem cells. Sensitivity of mammalian
cells (carrying the benzimidazole-resistant allele 200-Tyr)
lies between an IC50 around 0.25mM in HL60 cells and
20mM in Vero cells (nocodazole, another benzimidazole,
is, however, 10- to 20-fold more toxic; Katiyar et al., 1994).
This suggests that ABZ may also bind with low affinity to
mammalian b-tubulin, and/or the existence of another,
unknown, mode of action of ABZ that may be responsible
for ABZ side-effects in patients, as mentioned above. In
this respect, it is noteworthy to mention that Xiao et al.
(1995) found the downregulation of enzymes involved in
carbohydrate metabolism upon benzimidazole treatment
of rodents bearing E. granulosus metacestodes.
Novel chemotherapeutical treatment options
Novel and improved therapeutical tools are needed in
order to optimize treatment of CE and AE. They should
have a better selectivity, thus a much greater therapeutic
window than ABZ, and be parasitocidal rather than
parasitostatic. Unfortunately, the pharmaceutical industry
is not developing novel treatment options besides
benzimidazoles against theseneglecteddiseases.Therefore,
novel chemotherapeutics have to be identified issuing from
existing drugs by one of the following strategies: (1) in vitro
testing of broad-spectrum anti-infective drugs, either
in parallel with, or followed by, small animal experimen-
tation; (2) in vitro testing of drugs inhibiting proliferation
of cancer cells for their effects on the viability of
Echinococcusmetacestodes and protoscoleces.
Furthermore, employing the currently achieved
genomic sequencing efforts, the conventional strategies
(1) and (2)will be complemented by twomolecular genetic
and in silico approaches, namely (3) the exploitation of the
similarities between the parasite and mammalian signal-
lingmachineries, with a special focus on targeting specific
signalling receptors; and (4) the search for suitable
molecular targets for compounds of known modes of
action.
(1) Chemotherapeutical activities of anti-infective drugs
Besides benzimidazoles, promising compounds
with in vitro protoscolicidal action are cetrimide
(Frayha et al., 1981), and the ionophore monensin
(Rogan & Richards, 1986), but these drugs are rather
ineffective against metacestodes. The imidazothiazole
levamisole, an acetylcholine agonist, and the macrolide
antibioticum ivermectin, a chloride-channel activator
classically used against nematode infections, were
shown to exhibit in vitro activities similar to benzimi-
dazoles (Casado et al., 1989; Martinez et al., 1999; but see
also Reuter et al., 2006). In rodents infected with
E. multilocularis metacestodes, mytomicin C, piperazine
and quinolone derivates, alkylaminoethers, and
propargylic alcohols exhibited parasitostatic effects, at
either lower or comparable levels as benzimidazoles
(reviewed in Siles-Lucas & Hemphill, 2002). PZQ has
been used for the treatment of AE, but experimental
data in animals have shown that the efficacy of PZQ
against E. multilocularis metacestodes was not satisfac-
tory (Marchiondo et al., 1994). Also, treatment of
E. multilocularis-infected mice with alpha-difluoromethy-
lornithine was not successful (Miyaji et al., 1993).
When E. multilocularis metacestodes were treated with
the thiazolide nitazoxanide (NTZ), a broad-spectrum
anthelminthic also effective against enteric bacteria,
Giardia and Cryptosporidium (Hemphill et al., 2006),
0.3mM caused a total disintegration after 21 days, 3mM
after 14 days and 30mM after 7 days at most (Reuter et al.,
2006). NTZ was thus more efficient in vitro than ABZ
(see above). Ultrastructural analysis revealed that NTZ
induced significant distortion of the germinal layer in vitro
(Stettler et al., 2003) and severe damage in E. granulosus
protoscoleces and the germinal layer of in vitro cultured
E. granulosus metacestodes (Walker et al., 2004b). In vitro
studies on E. multilocularis and E. granulosus employing
NTZ derivatives (see Esposito et al., 2007; Hemphill et al.,
2007) showed that metacestodicidal and protoscolicidal
activity of this class of drugs depends largely on the
presence of the nitro-thiazole moiety (Stadelmann &
Hemphill, in preparation). Echinococcus multilocularis
metacestodes treated with 32mM NTZ for 14 days were
non-viable when introduced into susceptible mice for
5 months (Stettler et al., 2003). In another study,
metacestodes treated with the same amount of NTZ
were viable in gerbils (Reuter et al., 2006). In contrast to
ABZ, in vivo studies in rodents showed little or no effects
of thiazolides, most likely due to their rapid metabolism.
In this respect, Stettler et al. (2004) showed that NTZ,
orally applied to E. multilocularis-infected mice, either
alone or in combination with ABZ, exhibited a profound
antiparasitic efficacy, with the ABZ/NTZ combination
yielding the most promising results. Analysis of
pharmacokinetics showed that the half-life of ABZ-
sulphoxide, a metabolite of ABZ, increased upon
application of ABZ in combination with NTZ (Stettler
et al., 2004). Therefore, the increased efficacy observed in
mice could be a result of both the direct effects of NTZ
and ABZ on the parasite and the inhibition of ABZ
catabolism by NTZ. Combination treatment with ABZ/
NTZ at concentrations as low as 3 and 4mM, respectively,
for 3 weeks inhibited, however, re-growth of parasites
during 8 months of drug discontinuation and, also,
bioassay in gerbils did not result in viable parasite
infections (Reuter et al., 2006). Thus, combined ABZ/NTZ
treatment exhibited a parasitocidal effect. The mode of
action and especially targets of NTZ in Echinococcus are
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unknown. InG. lamblia, a nitroreductase was identified by
affinity chromatography and subsequent enzymological
studies as a potential target (Mu¨ller et al., 2007b).
Furthermore, recombinant protein disulphide isomerases
from G. lamblia and N. caninum were inhibited by NTZ
and other thiazolides (Mu¨ller et al., 2007a, 2008a).
The polyene macrolide amphotericin B (AMB) is an
antifungal compound binding to ergosterol in the cell
membrane, thus causing membrane depolarization and
cell damage by oxidative stress (Blum et al., 2008). In a
formulation as desoxycholate, it was shown to inhibit
E. multilocularis larval growth in vitro and in human
patients in vivo (Reuter et al., 2003a, b). Major drawbacks
of AMB are its intravenous application mode and its
nephrotoxic side-effects. Moreover, AMB is only para-
sitostatic (Reuter et al., 2003b). Nevertheless, a few cases
of progressive human AE have been treated with AMB,
and prolonged application of AMB over months to years
appears to be feasible, as side-effects have been milder
than expected (Reuter et al., 2003b). Itraconazole, an
antimycotic with a similar mode of action as AMB, was
also slightly effective against metacestodes, but only
parasitostatic (Reuter et al., 2006).
Isoprinosine, an inosine derivative commercialized as
an immunostimulant, affected viability of protoscoleces
in vitro, thus not mediated by the immune system of the
host (Lawton et al., 2001).
Artemisinin and artemisinin-derivatives are widely
used in malaria chemotherapy. In vitro testing on a
number of artemisinin-derivatives showed that artesu-
nate (AS) and dihydroartemisinin (DHA) at 40mM caused
considerable damage to metacestodes in vitro. However,
in vivo treatment in mice was ineffective. Again,
combination therapies of ABZ with DHA and AS,
respectively, were slightly more efficacous than ABZ
alone, but results closely missed statistical significance
(Spicher et al., 2008b).
(2) Studies on antiproliferative drugs
There are a number of links between growth of cancer
cells and Echinococcus and other parasites (reviewed in
Klinkert & Heussler, 2006), namely their proliferative
capacity, the potential to modulate the immune response,
the secretion of proteolytic enzymes in order to reach their
target sites or organs, and the capacitiy of metastasis
formation. Echinococcus multilocularis metacestodes
behave like malignant tumours, and there is an
association between the uncontrolled proliferation and
growth and the overexpression in metacestodes of a
family of proteins named 14-3-3 (Siles-Lucas et al., 1998,
2001). 14-3-3 proteins are found in all eukaryotic cells and
participate in protein kinase signalling pathways. They
function as phosphoserine/phosphothreonine-binding
modules and have an effect on phosphorylation-
dependent events such as DNA-damage checkpoints
and prevention of apoptosis (reviewed in Siles-Lucas &
Gottstein, 2003). Some 14-3-3 proteins have been found to
be aberrantly expressed in tumour cells, being either pro-
or antitumorigenic. In fact, when Echinococcus 14-3-3
sequences were aligned with other 14-3-3 isoforms of
other organisms, those overexpressed in metacestodes
were grouped with the tumour-growth-related zeta-
isoforms (Siles-Lucas et al., 2001). This indicates that
antitumour agents interacting with 14-3-3-triggered
pathways could have the potential to interfere in growth
of Echinococcus metacestodes.
Doxorubicin, or hydroxyldaunorubicin, is a DNA-
interacting drug widely used in chemotherapy, and is
commonly used in the treatment of a wide range of
cancers. The parasiticidal properties of doxorubicin
against the metacestode of E. multilocularis were
investigated after binding of that drug to polyisohex-
ylcyanoacrylate nanoparticles, a colloidal biodegradable
drug carrier. A reduction of the hepatic parasite
development and a reduced viability of the metaces-
tode were observed in mice injected with 5mg/kg
body weight, but 7.5mg/kg body weight did not
appear to be more efficient. Free doxorubicin or
unbound nanoparticles had no antiparasitic activity
(Liance et al., 1993).
Another class of antitumour agents with proven
antiparasitic activities are isoflavonoids. Isoflavonoids
are substances formed by plant tissue in response
to physiological stimuli such as infectious agents,
with reported anti-oxidant, antibacterial, antiviral and
antifungal activity (Dakora & Phillips, 1996). They are
composed of a characteristic 15-carbon backbone ring
structure connected by a heterocyclic pyrane (3-C) bridge
(C6–C3–C6) (Reynaud et al., 2005), with the two aromatic
rings generally containing a number of phenolic hydroxyl
groups. Genistein, a major component of soya, is the most
prominent isoflavonoid, and inhibits growth and metas-
tasis of a number of cancer cell lines (breast, prostate, skin,
colon). Genistein also stimulates the synthesis of
transforming growth factor-b (TGF-b), which itself
inhibits cancer cell proliferation (Messina, 1999). Besides
other targets, genistein acts on a number of signal-
ling pathways, by functioning as a kinase inhibitor
(tyrosine kinase, mitogen activated protein (MAP) kinase,
ribosomal S6 kinase). Our own studies showed that
genistein was highly effective against E. multilocularis
metacestodes in vitro (Naguleswaran et al., 2006).
However, genistein has a disadvantage, in that it also
exerts oestrogenic effects by binding to oestrogen
receptor-b (Pike et al., 1999), and this renders genistein
unfavourable for long-term treatment applications. Bind-
ing to the oestrogen receptor-b has been proven to take
place through the hydroxyl-group associated with the
B-ring of the molecule. We have therefore tested a number
of isoflavonoids in vitro, which do not carry this hydroxyl-
group and therefore do not meet the steric requirements
to bind to the oestrogen receptor-b. One of these
compounds, Rm6423, exhibits pronounced antiparasitic
activity against E. multilocularis metacestodes, as well as
against E. granulosus metacestodes and protoscoleces
(Naguleswaran et al., 2006). Further, examination of
culture medium revealed increased leakage of parasite
proteins into the medium during treatment, and
zymography demonstrated a loss in the activity of
metalloproteases. The molecular basis of the efficacy
of genistein and its derivative Rm6423 have not been
elucidated, but these compounds could interfere
in signalling, for instance through inhibiting the
tyrosine kinase activity associated with, for example, the
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epidermal growth factor receptor identified in E. multi-
locularis (Spiliotis et al., 2006).
2-Methoxyestradiol (2-ME), an endogenous metab-
olite of oestrogen with both anti-angiogenic and
antitumour effects (reviewed in Schumacher & Neu-
haus, 2001), was shown to downregulate the pro-
tumorigenic 14-3-3-z-isoform in a number of cancer
cell types (Kumar et al., 2003), an isoform also
overexpressed in Echinococcus metacestodes (Siles-
Lucas & Gottstein, 2003). Application of 2-ME
(2–10mM) to E. multilocularis metacestodes in vitro
caused severe damage and downscaled 14-3-3 tran-
scription levels. In vivo however, 2-ME had no
significant effects, although a combination therapy
comprised of ABZ and 2-ME produced slightly better
results than ABZ alone (Spicher et al., 2008a). The
mechanism of action of 2-ME in cancer cells has been
attributed to interference in microtubule stability and
dysregulation of hypoxia-inducible factor (Attalla et al.,
1996; Klauber et al., 1997; Mabjeesh et al., 2003),
inducing cancer cells to undergo apoptosis via extrinsic
and intrinsic pathways. It is not known how 2-ME
exerts its effects on Echinococcus.
NTZ, previously introduced as an anti-infective
drug, also inhibits the proliferation of colon cancer
cells in vitro, probably by interfering with glutathione-
S-transferase (GST) class p, an isoform overexpressed
in many proliferating cells (Mu¨ller et al., 2008b). In
E. granulosus and E. multilocularis, the only GSTs charac-
terized so far have some sequence homologies to the
mammalian class m (Liebau et al., 1996; Fernandez et al.,
2000). The catalytic properties of recombinant GST of
E. multilocularis had, however, higher similarities to
mammalian classes a and p, with, especially, a high
conjugating activity on ethacrynic acid, an anticancer
drug (Liebau et al., 1996). In principle, GSTs may have
two opposite effects on drugs, namely by inactivating
drugs or by activating ineffective pro-drugs. The latter
effects have been employed as an anticancer drug
strategy (Rooseboom et al., 2004) and may be further
developed as an anti-Echinococcus strategy.
Cyclosporin A (CA) is an inhibitor of the protein
phosphatase calcineurin and acts as an antiproliferative
for lymphocytes, employed mainly as an immuno-
suppressant after organ transplantation (Ozbay et al.,
2007). CA also exhibits anti-echinococcal activities in
mice. While administration of CA in five consecu-
tive daily doses, beginning 2 days prior to infection
with E. granulosus protsocoleces, resulted in significant
reduction in cyst numbers and cyst masses measured
at 20 weeks post-infection, no changes in cyst mass
and numbers were noted when the drug was
administered 18 weeks post-infection. Ultrastructural
examination of the germinal membrane and laminated
layer of late-treated E. granulosus revealed abnormal-
ities in all cysts studied, whereas control and early-
treated hydatids were normal (Hurd et al., 1993). In
contrast to E. granulosus, CA did not have any
antiparasitic activity against E. multilocularis infection
in mice, and its immunosuppressive activity was
shown to be more effective than its parasitostatic effect
(Liance et al., 1992). Potential targets for CA in
Echinococcus are unknown.
(3) The Echinococcus signalling machinery as a novel drug
target
More recently, the excellent work of Brehm et al. has
shed light on a number of developmental factors that
E. multilocularismetacestodes share with other metazoans
(for a review refer to Brehm et al., 2006). These include
signalling systems that employ receptor tyrosine kinases
of the epidermal growth factor (EGF) (Spiliotis et al., 2003,
2006), the insulin/insulin-like growth factor (Ins/IGF)-
receptor families (Konrad et al., 2003), and the surface
serine/threonine kinases of the closely related transform-
ing growth factor-b (TGF-b) and bone morphogenetic
protein (BMP)-receptor families (Zavala-Gongora et al.,
2006). A cytokine that has significant homologies to
mammalian EGF has been shown to be tenfold
upregulated in E. multilocularis metacestodes cultured
under conditions that promote growth and differentiation
(Spiliotis et al., 2003). EmSkip, a novel member of the
SNW/SKIP family of transcriptional co-regulators was
found to be expressed in the Echinococcus metacestodes
and protoscoleces during an infection of the intermediate
host (Gelmedin et al., 2005). EmSkip interacts with
EmSmadA and EmSmadB, two TGF-b/BMP signal
transducers of E. multilocularis (Zavala-Gongora et al.,
2003), indicating a role of this protein in TGF-b signalling
processes in the parasite. In addition, downstream
signalling elements of the MAP kinase cascade have
been identified and characterized (Spiliotis & Brehm,
2004; Spiliotis et al., 2005, 2006). The Echinococcus MAP
kinase cascade factors share similarities, but also have
differences, compared to their mammalian counterparts.
The differences would represent prime candidate targets
for the development of novel anthelminthic drugs. For
instance, analysis of receptor activation has shown that
the E. multilocularis insulin receptor EmIR interacts
readily with insulin from the host. Moreover, TGF-b
receptor EmTR1, and possibly also the EGF-receptor
EmER, interact with their corresponding host ligands
(reviewed in Brehm et al., 2006). Thus, parasite and host
have evolved means of communication that would
largely influence the developmental biology of both
parasite and host. These receptor–ligand systems
certainly play a central role in host–parasite interaction
processes, and thus represent interesting drug targets
(Brehm et al., 2006). Cancer research has generated an
enormous number of compounds that interfere in the
functional activities of homologous receptors or respect-
ive downstream kinases (for review see Sioud & Leirdal,
2007), and the challenge will be to identify those drugs, or
respective derivatives, that inhibit these receptors, or the
corresponding downstream enzymes, in a parasite-
specific manner.
(4) In silico approaches
Mathis et al. (2005) have been the first to exploit the
current genomic sequence information to define a drug
target in Echinococcus in silico, and subsequently con-
firmed their hypothesis experimentally. In bacteria, the
ribosomes are important antibiotic targets, and macro-
lides such as erythromycin and clarithromycin are agents
that bind to the nascent peptide exit tunnel near
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the peptidyltransferase centre of large subunit rRNA
(Rodriguez-Fonseca et al., 1995). Higher eukaryotes carry
a guanine at position 2058 of both cytoplasmic and
mitochondrial rRNAs, and this modification at this
position has been demonstrated to confer the resistance
of eukaryotic cells to macrolide antibiotics. In contrast,
the mitochondrial rRNA of E. multilocularis carries an
adenine at sequence position 2058, which would be
predictive for susceptibility (Sander et al., 1997), while
the nucleus-encoded rRNA is characterized by a guanine
at 2058 (Mathis et al., 2005). Upon in vitro culture of
E. multilocularis metacestodes with clarithromycin, para-
sites, as expected, exhibited severely impaired growth
characteristics, presented morphologically altered mito-
chondria and displayed a lack of microtriches, all in a
dose-dependent manner. Adult worms were also severely
affected, lost their motility and displayed morphological
alterations such as shortening and constriction of prog-
lottids and increased vacuolization. This study (Mathis
et al., 2005) is the first in Echinococcus to encourage the use
of sequence-based in silico approaches for the exploitation
of drugs, the mode of action of which is well studied
at the molecular level and the corresponding target is
precisely defined. However, a prerequisite for this is the
availability of more comprehensive Echinococcus genome
sequence information. In 2008, shotgun sequencing of
the E. multilocularis genome (c. 270MB) was completed
(http://www.sanger.ac.uk/Projects/Echinococcus/).
This opens the door for the identification of drug targets
by affinity chromatography followed by mass spec-
trometry (MS)-based sequencing and for reverse genetics
by overexpressing or silencing genes of interest. Transient
transfections of primary cells of E. multilocularis have
already been performed (Spiliotis et al., 2008).
Concluding remarks
As outlined in this review, considerable efforts have
been undertaken in order to improve the therapeutical
options for the treatment of CE and AE. Benzimidazole-
based treatments have considerably improved the
prognosis of patients, but new developments are wanted
since the current treatments are only parasitostatic and
have numerous side-effects. Parasitocidal compounds
in vivo have not been identified to date, but drugs with
different modes of action, such as NTZ, AMB and
oestradiol- and artemisinin-derivatives, having shown
promising results in preclinical studies, may be tested in
combination with ABZ or related benzimidazoles in order
to develop a suitable parasiticidal therapy. So far,
academic institutions provide a scientific basis for novel
treatment options, but financial constraints constantly
limit the further development of promising therapies.
Therefore, considerably more input is needed by the
pharmaceutical industry and governmental agencies,
in order to provide solutions for these neglected
diseases. Clearly, a medium- to high-throughput meta-
cestode screening system, allowing preliminary in vitro
assessments of novel drug classes and respective
conclusions on structure–activity relationships, needs to
be developed. Besides traditional screening methods,
genomic approaches, focused on the discovery of the
receptor–ligand interactions and associated signalling
pathways that influence the parasite–host interactions,
will provide new opportunities and promising targets for
follow-up studies on novel therapeutical options.
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